Lithuanian Prostate Diagnostics Implementation Guide, published by Lithuanian Medical Library. This guide is not an authorized publication; it is the continuous build for version 0.0.1 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7LT/ig-lt-prostate/ and changes regularly. See the Directory of published versions

• Pasakojimo turinys
• XML
• JSON

: Prostate questionnaire answer options (illustrative)

Draft nuo 2026-03-31

Neapdorotas xml | Atsisiųsti

<CodeSystem xmlns="http://hl7.org/fhir">
  <id value="prostate-questionnaire-options"/>
  <language value="lt"/>
  <text>
    <status value="generated"/>
    <div xml:lang="lt" lang="lt"><hr/><p><b>Lithuanian</b></p><hr/><p class="res-header-id"><b>Generated Narrative: CodeSystem prostate-questionnaire-options</b></p><a name="lt-prostate-questionnaire-options"> </a><a name="lt-hcprostate-questionnaire-options"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p></div><p>This case-sensitive code system <code>https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options</code> defines the following codes:</p><table class="codes"><tr><td style="white-space:nowrap"><b>Code</b></td><td><b>Display</b></td></tr><tr><td style="white-space:nowrap">specimen-satisfactory<a name="lt-prostate-questionnaire-options-specimen-satisfactory"> </a></td><td>Specimen satisfactory for evaluation</td></tr><tr><td style="white-space:nowrap">specimen-limited<a name="lt-prostate-questionnaire-options-specimen-limited"> </a></td><td>Specimen satisfactory but limited</td></tr><tr><td style="white-space:nowrap">specimen-insufficient<a name="lt-prostate-questionnaire-options-specimen-insufficient"> </a></td><td>Insufficient tissue for diagnosis</td></tr><tr><td style="white-space:nowrap">treatment-unknown<a name="lt-prostate-questionnaire-options-treatment-unknown"> </a></td><td>Treatment effect unknown</td></tr><tr><td style="white-space:nowrap">treatment-unidentifiable<a name="lt-prostate-questionnaire-options-treatment-unidentifiable"> </a></td><td>Treatment effect unidentifiable</td></tr><tr><td style="white-space:nowrap">treatment-radiotherapy<a name="lt-prostate-questionnaire-options-treatment-radiotherapy"> </a></td><td>Observed radiotherapy effect</td></tr><tr><td style="white-space:nowrap">treatment-hormone<a name="lt-prostate-questionnaire-options-treatment-hormone"> </a></td><td>Observed hormone therapy effect</td></tr><tr><td style="white-space:nowrap">treatment-other<a name="lt-prostate-questionnaire-options-treatment-other"> </a></td><td>Observed other therapy effect</td></tr><tr><td style="white-space:nowrap">hist-acinar<a name="lt-prostate-questionnaire-options-hist-acinar"> </a></td><td>Acinar adenocarcinoma (conventional)</td></tr><tr><td style="white-space:nowrap">hist-acinar-signet-ring<a name="lt-prostate-questionnaire-options-hist-acinar-signet-ring"> </a></td><td>Acinar adenocarcinoma, signet-ring cell-like</td></tr><tr><td style="white-space:nowrap">hist-acinar-pleomorphic<a name="lt-prostate-questionnaire-options-hist-acinar-pleomorphic"> </a></td><td>Acinar adenocarcinoma, pleomorphic giant cell</td></tr><tr><td style="white-space:nowrap">hist-acinar-sarcomatoid<a name="lt-prostate-questionnaire-options-hist-acinar-sarcomatoid"> </a></td><td>Acinar adenocarcinoma, sarcomatoid</td></tr><tr><td style="white-space:nowrap">hist-acinar-pin-like<a name="lt-prostate-questionnaire-options-hist-acinar-pin-like"> </a></td><td>Acinar adenocarcinoma, PIN-like</td></tr><tr><td style="white-space:nowrap">hist-idc-isolated<a name="lt-prostate-questionnaire-options-hist-idc-isolated"> </a></td><td>Isolated intraductal carcinoma</td></tr><tr><td style="white-space:nowrap">hist-ductal<a name="lt-prostate-questionnaire-options-hist-ductal"> </a></td><td>Ductal adenocarcinoma</td></tr><tr><td style="white-space:nowrap">hist-adenosquamous<a name="lt-prostate-questionnaire-options-hist-adenosquamous"> </a></td><td>Adenosquamous carcinoma</td></tr><tr><td style="white-space:nowrap">hist-squamous<a name="lt-prostate-questionnaire-options-hist-squamous"> </a></td><td>Squamous cell carcinoma</td></tr><tr><td style="white-space:nowrap">hist-basal-cell<a name="lt-prostate-questionnaire-options-hist-basal-cell"> </a></td><td>Basal cell (adenoid cystic) carcinoma</td></tr><tr><td style="white-space:nowrap">hist-neuro-adeno<a name="lt-prostate-questionnaire-options-hist-neuro-adeno"> </a></td><td>Adenocarcinoma with neuroendocrine differentiation</td></tr><tr><td style="white-space:nowrap">hist-neuro-well-diff<a name="lt-prostate-questionnaire-options-hist-neuro-well-diff"> </a></td><td>Well-differentiated neuroendocrine tumor</td></tr><tr><td style="white-space:nowrap">hist-neuro-small-cell<a name="lt-prostate-questionnaire-options-hist-neuro-small-cell"> </a></td><td>Small cell neuroendocrine carcinoma</td></tr><tr><td style="white-space:nowrap">hist-neuro-large-cell<a name="lt-prostate-questionnaire-options-hist-neuro-large-cell"> </a></td><td>Large cell neuroendocrine carcinoma</td></tr><tr><td style="white-space:nowrap">hist-unassessable<a name="lt-prostate-questionnaire-options-hist-unassessable"> </a></td><td>Carcinoma, type unassessable</td></tr><tr><td style="white-space:nowrap">hist-other<a name="lt-prostate-questionnaire-options-hist-other"> </a></td><td>Other histological type (see comment)</td></tr><tr><td style="white-space:nowrap">isup-gg1<a name="lt-prostate-questionnaire-options-isup-gg1"> </a></td><td>ISUP Grade Group 1 (Gleason 3+3)</td></tr><tr><td style="white-space:nowrap">isup-gg2<a name="lt-prostate-questionnaire-options-isup-gg2"> </a></td><td>ISUP Grade Group 2 (Gleason 3+4)</td></tr><tr><td style="white-space:nowrap">isup-gg3<a name="lt-prostate-questionnaire-options-isup-gg3"> </a></td><td>ISUP Grade Group 3 (Gleason 4+3)</td></tr><tr><td style="white-space:nowrap">isup-gg4<a name="lt-prostate-questionnaire-options-isup-gg4"> </a></td><td>ISUP Grade Group 4 (Gleason 4+4 or equivalent)</td></tr><tr><td style="white-space:nowrap">isup-gg5<a name="lt-prostate-questionnaire-options-isup-gg5"> </a></td><td>ISUP Grade Group 5 (Gleason 4+5 / 5+4 / 5+5)</td></tr><tr><td style="white-space:nowrap">idc-absent<a name="lt-prostate-questionnaire-options-idc-absent"> </a></td><td>Intraductal carcinoma not identified</td></tr><tr><td style="white-space:nowrap">idc-present<a name="lt-prostate-questionnaire-options-idc-present"> </a></td><td>Intraductal carcinoma identifiable</td></tr><tr><td style="white-space:nowrap">cribriform-na<a name="lt-prostate-questionnaire-options-cribriform-na"> </a></td><td>Cribriform not applicable</td></tr><tr><td style="white-space:nowrap">cribriform-unknown<a name="lt-prostate-questionnaire-options-cribriform-unknown"> </a></td><td>Cribriform undefined</td></tr><tr><td style="white-space:nowrap">cribriform-present<a name="lt-prostate-questionnaire-options-cribriform-present"> </a></td><td>Cribriform identifiable</td></tr><tr><td style="white-space:nowrap">dre-not-done<a name="lt-prostate-questionnaire-options-dre-not-done"> </a></td><td>DRE not performed</td></tr><tr><td style="white-space:nowrap">dre-normal<a name="lt-prostate-questionnaire-options-dre-normal"> </a></td><td>DRE normal</td></tr><tr><td style="white-space:nowrap">dre-suspicious<a name="lt-prostate-questionnaire-options-dre-suspicious"> </a></td><td>DRE suspicious</td></tr><tr><td style="white-space:nowrap">referral-screening<a name="lt-prostate-questionnaire-options-referral-screening"> </a></td><td>Referral for screening</td></tr><tr><td style="white-space:nowrap">referral-elevated-psa<a name="lt-prostate-questionnaire-options-referral-elevated-psa"> </a></td><td>Referral for elevated PSA</td></tr><tr><td style="white-space:nowrap">referral-other<a name="lt-prostate-questionnaire-options-referral-other"> </a></td><td>Other referral reason</td></tr><tr><td style="white-space:nowrap">ynk-yes<a name="lt-prostate-questionnaire-options-ynk-yes"> </a></td><td>Yes</td></tr><tr><td style="white-space:nowrap">ynk-no<a name="lt-prostate-questionnaire-options-ynk-no"> </a></td><td>No</td></tr><tr><td style="white-space:nowrap">ynk-unknown<a name="lt-prostate-questionnaire-options-ynk-unknown"> </a></td><td>Unknown</td></tr><tr><td style="white-space:nowrap">pirads-cat-1-2<a name="lt-prostate-questionnaire-options-pirads-cat-1-2"> </a></td><td>PI-RADS 1–2</td></tr><tr><td style="white-space:nowrap">pirads-cat-3<a name="lt-prostate-questionnaire-options-pirads-cat-3"> </a></td><td>PI-RADS 3</td></tr><tr><td style="white-space:nowrap">pirads-cat-4<a name="lt-prostate-questionnaire-options-pirads-cat-4"> </a></td><td>PI-RADS 4</td></tr><tr><td style="white-space:nowrap">pirads-cat-5<a name="lt-prostate-questionnaire-options-pirads-cat-5"> </a></td><td>PI-RADS 5</td></tr><tr><td style="white-space:nowrap">pattern4-pct-na<a name="lt-prostate-questionnaire-options-pattern4-pct-na"> </a></td><td>Pattern 4 %: not applicable</td></tr><tr><td style="white-space:nowrap">pattern4-pct-lte5<a name="lt-prostate-questionnaire-options-pattern4-pct-lte5"> </a></td><td>Pattern 4 %: ≤5%</td></tr><tr><td style="white-space:nowrap">pattern4-pct-6-10<a name="lt-prostate-questionnaire-options-pattern4-pct-6-10"> </a></td><td>Pattern 4 %: 6–10%</td></tr><tr><td style="white-space:nowrap">pattern4-pct-gt40<a name="lt-prostate-questionnaire-options-pattern4-pct-gt40"> </a></td><td>Pattern 4 %: &gt;40%</td></tr><tr><td style="white-space:nowrap">tumor-pct-lt1<a name="lt-prostate-questionnaire-options-tumor-pct-lt1"> </a></td><td>Tumour % in biopsy: &lt;1%</td></tr><tr><td style="white-space:nowrap">tumor-pct-1-5<a name="lt-prostate-questionnaire-options-tumor-pct-1-5"> </a></td><td>Tumour % in biopsy: 1–5%</td></tr><tr><td style="white-space:nowrap">tumor-pct-gt90<a name="lt-prostate-questionnaire-options-tumor-pct-gt90"> </a></td><td>Tumour % in biopsy: &gt;90%</td></tr><tr><td style="white-space:nowrap">tumor-pct-uneval<a name="lt-prostate-questionnaire-options-tumor-pct-uneval"> </a></td><td>Tumour %: cannot be evaluated</td></tr><tr><td style="white-space:nowrap">periprostatic-unknown<a name="lt-prostate-questionnaire-options-periprostatic-unknown"> </a></td><td>Periprostatic fat invasion: unidentifiable</td></tr><tr><td style="white-space:nowrap">periprostatic-absent<a name="lt-prostate-questionnaire-options-periprostatic-absent"> </a></td><td>Periprostatic fat invasion: not identified</td></tr><tr><td style="white-space:nowrap">periprostatic-present<a name="lt-prostate-questionnaire-options-periprostatic-present"> </a></td><td>Periprostatic fat invasion: present</td></tr><tr><td style="white-space:nowrap">biopsy-initial<a name="lt-prostate-questionnaire-options-biopsy-initial"> </a></td><td>Initial biopsy</td></tr><tr><td style="white-space:nowrap">biopsy-repeat<a name="lt-prostate-questionnaire-options-biopsy-repeat"> </a></td><td>Repeat biopsy</td></tr><tr><td style="white-space:nowrap">fixative-buffered-formalin<a name="lt-prostate-questionnaire-options-fixative-buffered-formalin"> </a></td><td>10% buffered formalin</td></tr><tr><td style="white-space:nowrap">fixative-unfixed<a name="lt-prostate-questionnaire-options-fixative-unfixed"> </a></td><td>Unfixed (no fixative)</td></tr><tr><td style="white-space:nowrap">dx-n40-gph<a name="lt-prostate-questionnaire-options-dx-n40-gph"> </a></td><td>N40 Glandular prostatic hyperplasia</td></tr><tr><td style="white-space:nowrap">dx-c61<a name="lt-prostate-questionnaire-options-dx-c61"> </a></td><td>C61 Malignant neoplasm of prostate</td></tr><tr><td style="white-space:nowrap">ct-1c<a name="lt-prostate-questionnaire-options-ct-1c"> </a></td><td>cT1c</td></tr><tr><td style="white-space:nowrap">ct-2<a name="lt-prostate-questionnaire-options-ct-2"> </a></td><td>cT2</td></tr><tr><td style="white-space:nowrap">ct-3a<a name="lt-prostate-questionnaire-options-ct-3a"> </a></td><td>cT3a</td></tr><tr><td style="white-space:nowrap">ct-3b<a name="lt-prostate-questionnaire-options-ct-3b"> </a></td><td>cT3b</td></tr><tr><td style="white-space:nowrap">op-transperineal<a name="lt-prostate-questionnaire-options-op-transperineal"> </a></td><td>Transperineal biopsy</td></tr><tr><td style="white-space:nowrap">op-transrectal<a name="lt-prostate-questionnaire-options-op-transrectal"> </a></td><td>Transrectal biopsy</td></tr><tr><td style="white-space:nowrap">proc-systematic<a name="lt-prostate-questionnaire-options-proc-systematic"> </a></td><td>Systematic biopsy</td></tr><tr><td style="white-space:nowrap">proc-adaptive<a name="lt-prostate-questionnaire-options-proc-adaptive"> </a></td><td>Adaptive biopsy</td></tr><tr><td style="white-space:nowrap">proc-systematic-targeted<a name="lt-prostate-questionnaire-options-proc-systematic-targeted"> </a></td><td>Systematic + targeted biopsy</td></tr><tr><td style="white-space:nowrap">proc-applicative-perifocal<a name="lt-prostate-questionnaire-options-proc-applicative-perifocal"> </a></td><td>Applicative + perifocal biopsy</td></tr><tr><td style="white-space:nowrap">perineural-present<a name="lt-prostate-questionnaire-options-perineural-present"> </a></td><td>Perineural invasion present</td></tr><tr><td style="white-space:nowrap">perineural-absent<a name="lt-prostate-questionnaire-options-perineural-absent"> </a></td><td>Perineural invasion not identified</td></tr><tr><td style="white-space:nowrap">perineural-ambiguous<a name="lt-prostate-questionnaire-options-perineural-ambiguous"> </a></td><td>Perineural invasion ambiguous</td></tr><tr><td style="white-space:nowrap">perineural-uneval<a name="lt-prostate-questionnaire-options-perineural-uneval"> </a></td><td>Perineural invasion cannot be evaluated</td></tr><tr><td style="white-space:nowrap">lymphovascular-present<a name="lt-prostate-questionnaire-options-lymphovascular-present"> </a></td><td>Lymphovascular invasion identifiable</td></tr><tr><td style="white-space:nowrap">lymphovascular-absent<a name="lt-prostate-questionnaire-options-lymphovascular-absent"> </a></td><td>Lymphovascular invasion unidentifiable / not available</td></tr><tr><td style="white-space:nowrap">lymphovascular-ambiguous<a name="lt-prostate-questionnaire-options-lymphovascular-ambiguous"> </a></td><td>Lymphovascular invasion ambiguous</td></tr><tr><td style="white-space:nowrap">lymphovascular-uneval<a name="lt-prostate-questionnaire-options-lymphovascular-uneval"> </a></td><td>Lymphovascular invasion cannot be evaluated</td></tr></table></div>
  </text>
  <url
       value="https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options"/>
  <version value="0.0.1"/>
  <name value="ProstateQuestionnaireOptions"/>
  <title value="Prostate questionnaire answer options (illustrative)"/>
  <status value="draft"/>
  <experimental value="true"/>
  <date value="2026-03-31T08:54:25+00:00"/>
  <publisher value="Lithuanian Medical Library"/>
  <contact>
    <name value="Lithuanian Medical Library"/>
    <telecom>
      <system value="url"/>
      <value value="https://medicinosnk.lt"/>
    </telecom>
    <telecom>
      <system value="email"/>
      <value value="info@medicinosnk.lt"/>
    </telecom>
  </contact>
  <description
               value="Illustrative codes for **Questionnaire** answer options for prostate ESPBI-style forms in this IG. Register or replace with national coded values in production."/>
  <jurisdiction>
    <coding>
      <system value="urn:iso:std:iso:3166"/>
      <code value="LT"/>
    </coding>
  </jurisdiction>
  <caseSensitive value="true"/>
  <content value="complete"/>
  <count value="82"/>
  <concept>
    <code value="specimen-satisfactory"/>
    <display value="Specimen satisfactory for evaluation"/>
  </concept>
  <concept>
    <code value="specimen-limited"/>
    <display value="Specimen satisfactory but limited"/>
  </concept>
  <concept>
    <code value="specimen-insufficient"/>
    <display value="Insufficient tissue for diagnosis"/>
  </concept>
  <concept>
    <code value="treatment-unknown"/>
    <display value="Treatment effect unknown"/>
  </concept>
  <concept>
    <code value="treatment-unidentifiable"/>
    <display value="Treatment effect unidentifiable"/>
  </concept>
  <concept>
    <code value="treatment-radiotherapy"/>
    <display value="Observed radiotherapy effect"/>
  </concept>
  <concept>
    <code value="treatment-hormone"/>
    <display value="Observed hormone therapy effect"/>
  </concept>
  <concept>
    <code value="treatment-other"/>
    <display value="Observed other therapy effect"/>
  </concept>
  <concept>
    <code value="hist-acinar"/>
    <display value="Acinar adenocarcinoma (conventional)"/>
  </concept>
  <concept>
    <code value="hist-acinar-signet-ring"/>
    <display value="Acinar adenocarcinoma, signet-ring cell-like"/>
  </concept>
  <concept>
    <code value="hist-acinar-pleomorphic"/>
    <display value="Acinar adenocarcinoma, pleomorphic giant cell"/>
  </concept>
  <concept>
    <code value="hist-acinar-sarcomatoid"/>
    <display value="Acinar adenocarcinoma, sarcomatoid"/>
  </concept>
  <concept>
    <code value="hist-acinar-pin-like"/>
    <display value="Acinar adenocarcinoma, PIN-like"/>
  </concept>
  <concept>
    <code value="hist-idc-isolated"/>
    <display value="Isolated intraductal carcinoma"/>
  </concept>
  <concept>
    <code value="hist-ductal"/>
    <display value="Ductal adenocarcinoma"/>
  </concept>
  <concept>
    <code value="hist-adenosquamous"/>
    <display value="Adenosquamous carcinoma"/>
  </concept>
  <concept>
    <code value="hist-squamous"/>
    <display value="Squamous cell carcinoma"/>
  </concept>
  <concept>
    <code value="hist-basal-cell"/>
    <display value="Basal cell (adenoid cystic) carcinoma"/>
  </concept>
  <concept>
    <code value="hist-neuro-adeno"/>
    <display value="Adenocarcinoma with neuroendocrine differentiation"/>
  </concept>
  <concept>
    <code value="hist-neuro-well-diff"/>
    <display value="Well-differentiated neuroendocrine tumor"/>
  </concept>
  <concept>
    <code value="hist-neuro-small-cell"/>
    <display value="Small cell neuroendocrine carcinoma"/>
  </concept>
  <concept>
    <code value="hist-neuro-large-cell"/>
    <display value="Large cell neuroendocrine carcinoma"/>
  </concept>
  <concept>
    <code value="hist-unassessable"/>
    <display value="Carcinoma, type unassessable"/>
  </concept>
  <concept>
    <code value="hist-other"/>
    <display value="Other histological type (see comment)"/>
  </concept>
  <concept>
    <code value="isup-gg1"/>
    <display value="ISUP Grade Group 1 (Gleason 3+3)"/>
  </concept>
  <concept>
    <code value="isup-gg2"/>
    <display value="ISUP Grade Group 2 (Gleason 3+4)"/>
  </concept>
  <concept>
    <code value="isup-gg3"/>
    <display value="ISUP Grade Group 3 (Gleason 4+3)"/>
  </concept>
  <concept>
    <code value="isup-gg4"/>
    <display value="ISUP Grade Group 4 (Gleason 4+4 or equivalent)"/>
  </concept>
  <concept>
    <code value="isup-gg5"/>
    <display value="ISUP Grade Group 5 (Gleason 4+5 / 5+4 / 5+5)"/>
  </concept>
  <concept>
    <code value="idc-absent"/>
    <display value="Intraductal carcinoma not identified"/>
  </concept>
  <concept>
    <code value="idc-present"/>
    <display value="Intraductal carcinoma identifiable"/>
  </concept>
  <concept>
    <code value="cribriform-na"/>
    <display value="Cribriform not applicable"/>
  </concept>
  <concept>
    <code value="cribriform-unknown"/>
    <display value="Cribriform undefined"/>
  </concept>
  <concept>
    <code value="cribriform-present"/>
    <display value="Cribriform identifiable"/>
  </concept>
  <concept>
    <code value="dre-not-done"/>
    <display value="DRE not performed"/>
  </concept>
  <concept>
    <code value="dre-normal"/>
    <display value="DRE normal"/>
  </concept>
  <concept>
    <code value="dre-suspicious"/>
    <display value="DRE suspicious"/>
  </concept>
  <concept>
    <code value="referral-screening"/>
    <display value="Referral for screening"/>
  </concept>
  <concept>
    <code value="referral-elevated-psa"/>
    <display value="Referral for elevated PSA"/>
  </concept>
  <concept>
    <code value="referral-other"/>
    <display value="Other referral reason"/>
  </concept>
  <concept>
    <code value="ynk-yes"/>
    <display value="Yes"/>
  </concept>
  <concept>
    <code value="ynk-no"/>
    <display value="No"/>
  </concept>
  <concept>
    <code value="ynk-unknown"/>
    <display value="Unknown"/>
  </concept>
  <concept>
    <code value="pirads-cat-1-2"/>
    <display value="PI-RADS 1–2"/>
  </concept>
  <concept>
    <code value="pirads-cat-3"/>
    <display value="PI-RADS 3"/>
  </concept>
  <concept>
    <code value="pirads-cat-4"/>
    <display value="PI-RADS 4"/>
  </concept>
  <concept>
    <code value="pirads-cat-5"/>
    <display value="PI-RADS 5"/>
  </concept>
  <concept>
    <code value="pattern4-pct-na"/>
    <display value="Pattern 4 %: not applicable"/>
  </concept>
  <concept>
    <code value="pattern4-pct-lte5"/>
    <display value="Pattern 4 %: ≤5%"/>
  </concept>
  <concept>
    <code value="pattern4-pct-6-10"/>
    <display value="Pattern 4 %: 6–10%"/>
  </concept>
  <concept>
    <code value="pattern4-pct-gt40"/>
    <display value="Pattern 4 %: &gt;40%"/>
  </concept>
  <concept>
    <code value="tumor-pct-lt1"/>
    <display value="Tumour % in biopsy: &lt;1%"/>
  </concept>
  <concept>
    <code value="tumor-pct-1-5"/>
    <display value="Tumour % in biopsy: 1–5%"/>
  </concept>
  <concept>
    <code value="tumor-pct-gt90"/>
    <display value="Tumour % in biopsy: &gt;90%"/>
  </concept>
  <concept>
    <code value="tumor-pct-uneval"/>
    <display value="Tumour %: cannot be evaluated"/>
  </concept>
  <concept>
    <code value="periprostatic-unknown"/>
    <display value="Periprostatic fat invasion: unidentifiable"/>
  </concept>
  <concept>
    <code value="periprostatic-absent"/>
    <display value="Periprostatic fat invasion: not identified"/>
  </concept>
  <concept>
    <code value="periprostatic-present"/>
    <display value="Periprostatic fat invasion: present"/>
  </concept>
  <concept>
    <code value="biopsy-initial"/>
    <display value="Initial biopsy"/>
  </concept>
  <concept>
    <code value="biopsy-repeat"/>
    <display value="Repeat biopsy"/>
  </concept>
  <concept>
    <code value="fixative-buffered-formalin"/>
    <display value="10% buffered formalin"/>
  </concept>
  <concept>
    <code value="fixative-unfixed"/>
    <display value="Unfixed (no fixative)"/>
  </concept>
  <concept>
    <code value="dx-n40-gph"/>
    <display value="N40 Glandular prostatic hyperplasia"/>
  </concept>
  <concept>
    <code value="dx-c61"/>
    <display value="C61 Malignant neoplasm of prostate"/>
  </concept>
  <concept>
    <code value="ct-1c"/>
    <display value="cT1c"/>
  </concept>
  <concept>
    <code value="ct-2"/>
    <display value="cT2"/>
  </concept>
  <concept>
    <code value="ct-3a"/>
    <display value="cT3a"/>
  </concept>
  <concept>
    <code value="ct-3b"/>
    <display value="cT3b"/>
  </concept>
  <concept>
    <code value="op-transperineal"/>
    <display value="Transperineal biopsy"/>
  </concept>
  <concept>
    <code value="op-transrectal"/>
    <display value="Transrectal biopsy"/>
  </concept>
  <concept>
    <code value="proc-systematic"/>
    <display value="Systematic biopsy"/>
  </concept>
  <concept>
    <code value="proc-adaptive"/>
    <display value="Adaptive biopsy"/>
  </concept>
  <concept>
    <code value="proc-systematic-targeted"/>
    <display value="Systematic + targeted biopsy"/>
  </concept>
  <concept>
    <code value="proc-applicative-perifocal"/>
    <display value="Applicative + perifocal biopsy"/>
  </concept>
  <concept>
    <code value="perineural-present"/>
    <display value="Perineural invasion present"/>
  </concept>
  <concept>
    <code value="perineural-absent"/>
    <display value="Perineural invasion not identified"/>
  </concept>
  <concept>
    <code value="perineural-ambiguous"/>
    <display value="Perineural invasion ambiguous"/>
  </concept>
  <concept>
    <code value="perineural-uneval"/>
    <display value="Perineural invasion cannot be evaluated"/>
  </concept>
  <concept>
    <code value="lymphovascular-present"/>
    <display value="Lymphovascular invasion identifiable"/>
  </concept>
  <concept>
    <code value="lymphovascular-absent"/>
    <display value="Lymphovascular invasion unidentifiable / not available"/>
  </concept>
  <concept>
    <code value="lymphovascular-ambiguous"/>
    <display value="Lymphovascular invasion ambiguous"/>
  </concept>
  <concept>
    <code value="lymphovascular-uneval"/>
    <display value="Lymphovascular invasion cannot be evaluated"/>
  </concept>
</CodeSystem>